G. Kimmel, “Brodalumab in the treatment of moderate-to-severe psoriasis in patients refractory to anti-interleukin-17A therapies: Evaluation of secondary endpoints”, J of Skin, vol. 5, no. 5, pp. 524–529, Sep. 2021.